MAMashael Al-Luhaybi

Mashael Al-Luhaybi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mashael Al-Luhaybi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EM-Optimized Parameter Learning Framework for Interpretable Modeling of Therapeutic Activity and Adverse Side Effects in Personalized Hypertension Treatment

    by Mashael Al-Luhaybi

    Accurate prediction of pharmacological activity and associated therapeutic side effects is essential for advancing personalized medicine, particularly in hypertension therapy where patients’ responses vary depending on their health profiles and comorbidities. However, existing machine learning approaches face challenges in minimizing uncertainty specifically when targeting exploiting explainable models for ethical and personalized hypertension treatments. Moreover, pharmacological-hypertension datasets often contain missing and heterogeneous data due to incomplete side-effect reports which consequently reduce likelihood estimation and posterior calibration of the learned models. To address these challenges, a novel uncertainty-aware probabilistic learning framework based on Bayesian Networks (BNs) optimized via the Expectation–Maximization (EM) algorithm is proposed to reduce uncertainties through higher likelihood estimation for hypertension medications. This implementation extends previous EM-based probabilistic models by integrating uncertainty evaluation using influence strength and sensitivity analysis to enhance interpretability and reliability. The BN–EM framework learns dependencies between drug-related attributes such as drug classes, pregnancy categories, and brand names to predict side effects and activity levels. Three probabilistic experiments were conducted to assess the proposed parameter learning approach. The BN–EM model outperformed Tree-Augmented Naïve Bayes (TAN) and Naïve Bayes (NB), achieving the highest micro-averaged accuracy of 97.03%, compared to 95.48% and 89.55%, respectively. These findings highlight the potential of EM-optimized probabilistic modeling to support transparent and clinically interpretable personalized hypertension therapy.

  • Predicting Academic Performance: A Bootstrapping Approach for Learning Dynamic Bayesian Networks

    by Mashael Al-Luhaybi, Leila Yousefi, Stephen Swift, Steve Counsell, Allan Tucker


  • Predicting Disease Complications Using a Stepwise Hidden Variable Approach for Learning Dynamic Bayesian Networks

    by Leila Yousefi, Allan Tucker, Mashael Al-Luhaybi, Lucia Saachi, Riccardo Bellazzi, Luca Chiovato

    Predicting Diabetes Type 2 Mellitus (T2DM) complications such as retinopathy and liver disease is still a challenge despite being a growing public health concern worldwide. This is due to the complex interactions between complications and other features, as well as between the different complications, themselves. What is more, there are likely to be many unmeasured effects that impact the disease progression of different patients. Probabilistic graphical models such as Dynamic Bayesian Networks (DBNs) have demonstrated much promise in the modeling of disease progression and they can naturally incorporate hidden (latent) variables using the EM algorithm. Unlike deep learning approaches that attempt to model complex interactions in data by using a large number of hidden variables, we adopt a different approach. We are interested in models that not only capture unmeasured effects but are also transparent in how they model data so that knowledge about disease processes can be extracted and trust in the model can be maintained by clinicians. As a result, we have developed a step-wise hidden variable structure learning process that incrementally adds hidden variables based on the IC* algorithm. To the best of our knowledge, this is the first study for classifying disease complication using a step-wise learning methodology for identifying hidden and T2DM features with a DBN structure from clinical data. Our extensive set of experiments show that the proposed method improves classification accuracy, identifying the correct number of hidden variables, and targeting their precise location within the network structure.